US HB1790 | 2023-2024 | 118th Congress
Status
Spectrum: Bipartisan Bill
Status: Introduced on March 24 2023 - 25% progression
Action: 2023-03-31 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on March 24 2023 - 25% progression
Action: 2023-03-31 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Summary
To direct the Secretary of Health and Human Services to evaluate the extent to which the substitution of interchangeable biological products is impacted by differences between the system for determining a biological product to be interchangeable and the system for assigning therapeutic equivalence ratings to drugs, and for other purposes.
Title
Biologics Competition Act of 2023
Sponsors
| Rep. Mariannette Miller-Meeks [R-IA] | Rep. Nanette Barragan [D-CA] | Rep. Greg Murphy [R-NC] | Rep. Ann Kuster [D-NH] |
| Rep. Dan Crenshaw [R-TX] |
History
| Date | Chamber | Action |
|---|---|---|
| 2023-03-31 | House | Referred to the Subcommittee on Health. |
| 2023-03-24 | House | Referred to the House Committee on Energy and Commerce. |
| 2023-03-24 | House | Introduced in House |
Subjects
US Congress State Sources
| Type | Source |
|---|---|
| Summary | https://www.congress.gov/bill/118th-congress/house-bill/1790/all-info |
| Text | https://www.congress.gov/118/bills/hr1790/BILLS-118hr1790ih.pdf |
